Volume : 12, Issue : 11, November – 2025
Title:
FORMULATION AND IN VITRO EVALUATION OF GRANISETRON MOUTH-DISSOLVING TABLETS BY USING DIFFERENT GRADES OF SUPER DISINTEGRANTS
Authors :
Iqra, Sameena Begum*, Ayesha Farhath Fathima, Sameera Fatima, Suchismita Pani
Abstract :
Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Granisetron is extensively metabolised by the liver. To overcome these drawbacks, a mouth-dissolving tablet was a suitable dosage form as it bypasses metabolism. Granisetron is coming under class II of the BCS classification. In the present investigation, an attempt has been made to design and develop a Granisetron Mouth dissolving Tablet using Croscarmellose Sodium, Crospovidone and Sodium starch Glycolate as superdisintegrants with a view to obtaining rapid disintegration when held above the tongue, permitting direct absorption of the active ingredient by the oral mucosa, and it also bypasses fast pass metabolism and improves the bioavailability. FTIR studies revealed that the drug and excipients were compatible with each other. DSC studies were carried out to know the thermal stabilities of the drug and physical mixture of drug and excipients used for formulation, and it was concluded that the drug and polymers are thermally stable after the above formulations. Wet granulation methods were adopted for the preparation of Granisetron Mouth dissolving granules, and the evaluation results of all the precompression parameters satisfied the acceptance criteria that showing excellent flow properties of the granules. Different post-compression characterisation of the tablet was carried out, and the result satisfied the pharmacopoeia specifications. In vitro release studies were carried out in a USP II paddle-type dissolution apparatus for different formulations. In vitro release kinetic studies were carried out for zero-order and first-order kinetic models. Accelerated stability studies were carried out to confirm the stability of dosage forms, and the optimised formulation was found to be stable within an acceptable range.
Key Words: Mouth dissolving, Granisetron, Croscarmellose Sodium, crospovidone, Sodium starch glycolate
Cite This Article:
Please cite this article in press Sameena Begum et al., Formulation And In Vitro Evaluation Of Granisetron Mouth-Dissolving Tablets By Using Different Grades Of Super disintegrants, Indo Am. J. P. Sci, 2025; 12(11).
REFERENCES:
1. Leon Lachmann, Herbert A, Liberman, Joseph L. Kaing, The theory and practice of Industrial Pharmacy:293-303.
2. Aulton`s Pharmaceutics, The design & manufacture of medicines, Biopharmaceutics and pharmacokinetics, A Treatise, second edition, Valabh Prakashan, 315-84.
3. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998; 50(4): 375-82.
4. M. Akbar, N. Panda, AV Reddy, “Formulation and Evaluation of Doxofylline Sublingual Tablets Using Sodium Starch Glycolate and Crosscarmellose Sodium as Superdisintegrant” Int. J. of Pharm. Res. & All. Sci. 2015; 4(2):90-100.
5. Niranjan Panda, Afshan Sultana, A Venkateswar Reddy, G. V. Subba Reddy, M.S.Ansari: Formulation Design and Study the effect of Polyplasdone-XL and AC-Di-Sol on Release Profile of Doxofylline Immediate Release Tablets. Int. J. Pharm. Sci. Rev. Res., 32(2), 2015: 67-76.
6. Joshi P, Manju, Fateh MV, Raghavendra Rao N.G. Review on Mouth Dissolving Tablet. Asian Journal of Pharmaceutical Research. 2019;9(1): 42-54.
7. Upward J.W, Amold B.D.C, Link C, Piere D.M., Allen A., Tasker, T.C.G. The Clinical Pharmacology of Granisetron, a novel specific 5-HT3 antagonist. Eur. J. Cancer.1990; 26: S12-S15.
8. Yarker, Y.E., McTavish, D. Granisetron. Drugs. 1994; 48: 761–793.5. Https://pubchem.ncbi.nlm.nih.gov/compound/Granisetron-hydrochloride.
9. Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38.
10. Tan M: Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71.
11. Feyer P, Seegenschmiedt MH, Steingraeber M: Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies. Support Care Cancer. 2005 Sep;13(9):671-8. Epub 2005 Jul 26.
12. Santosh RK, Kumari A, “Superdisintegrant: crucial elements for mouth dissolving tablets” Journal of Drug Delivery and Therapeutics, 2019; 9(2): 461-468. DOI https://doi.org/10.22270/jddt.v9i2.2480.
13. Pawar C, Mutha SS, Bhise SV, Borawake PD, “Formulation and evaluation of mouth dissolving tablet of meloxicam using natural superdisintegrants. AJPCR, 2020; 13(2): 197-03.
14. Gamal M, Zayed AS, Rasoulae M, Ibrahimac M, “In vitro and in vivo characterization of domperidone-loaded fast dissolving buccal films” SPJ, 2020; 28(3): 266-273.
15. Damodar R, Movva B, Mallikarjun PN, Chaitanya P, Kona N, Varsha PV, “Formulation and evaluation of fast dissolving tablets of diclofenac sodium by novel hole technology” Mol Pharm Org Process Res, 2014; 2: 1-6.
16. Ratnaparkhi MP, “Formulation and development of taste masked orally disintegrating tablets of perindopril erbu Bühler, Volker (2005). Excipients for Pharmaceuticals – Povidone, Crospovidone and Copovidone. Berlin, Heidelberg, New York.
17. Abikesh Prasada Kumar Mahapatra, Niranjan Panda, Neelkant Prasad, Basudev Paul and Abhiram Rout; Increasing Efficiency of Transdermal Drug Delivery Systems Using Some Novel Penetration Enhancement Techniques – A Critical Review, International Journal of Life Science and Pharma Research, doi 10.22376/ijlpr.2023.13.6.P51-P77.
18. Bangale GS, Yadav GJ, Shinde GV, and Stephen Rathinaraj B: New Generation of Mouth dissolving Tablets: Recent Advances and Future Prospects. International Journal of Pharmacy and Pharmaceutical Science Research 2011; 1(2): 52-62.
19. Harsoliya MS, Pathan JK, and Shruti S: A Review Formulation of Mouth Dissolving Tablet, International Journal of Pharmaceutical and Clinical Science 2011; 1(1): 1-8.
20. Mishra DN, Bimodal M, Singh SK, Vijaya Kumar SG (2006) Spray dried excipient base: a novel technique for the formulation of orally disintegrating tablets. Chem Pharm Bull 54(1): 99-102
21. Rangu N, Kumari BC, Akula G, Jaswanth A. Formulation and Evaluation of Metoprolol Mouth dissolving Tablets by Super Disintegration Method. Asian J Pharm Res. 2018;8(3):119.
22. Mohire N, Yadav A, Gaikwad V. Novel Approaches in Development of Metronidazole Mouth dissolving Tablets. Res J Pharm Technol. 2009;2(2):283–6.
23. Mandlik S, Nandare D, Joshi M, Chudiwal P, Jain K. Statistical Optimization of Mouth dissolving Tablets Containing Telmisartan Using Factorial Design and Response Surface Methodology. Res J Pharm Technol. 2009;2(3):548–51.
24. Sanket K, Garg SK, Ajay A, Pradeep L. Fast dissolving tablets (FDTS): Recent trends and new market opportunities. Indo Am J Pharm Res 2014;4(7):3265-79.
25. Hadia Huma, Niranjan Panda, Vurathi Sreenivasulu, L.Rajesh Patro; Formulation Development and Evaluation of Mouth dissolving Tablets of Fexofenadine By Using Combinations of Superdisintegrants., Indo Am. J. P. Sci, 2023; 10 (05). 160-174.
26. Niranjan Panda et al Analyzing Dalfampridine’s Potential for Prolonged Release As A Matrix Tablet Using Various Grades of HPMC And Eudragit, Indo Am. J. P. Sci, 2024; 11(01).
27. Allen LV, Wang B, Davis JD, et al. US patent 5,1998; 807, 567. 68. Ghosh T, Ghosh A, Prasad D. A Review on New Generation Mouth dissolving Tablets and its future prospective. Int Journ Pharm Pharm Sci 2011.
28. Niranjan Panda et al, Formulation and Evaluation of Sublingual Tablets of Poorly Aqueous-Soluble Drug Ticagrelor Using Superdisintegrants., Indo Am. J. P. Sci, 2024; 11 (3).